The Levels of Prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in 180 normal men, 118 prostatic carcinoma (PCa) and 953 benign prostatic hypertrophy(BPH) were determined.
AbstractFrom November 1989 to August 1992,116 patients with prostatic hypertrophy weretreated by radiation of hypothalamus and pituitary gland areas. The radiation dose was4.8Gy/4F/2W.
Methods:Thirty two postoperative patients with benign prostatic hypertrophy (BPH) were randomly divided into two groups,passive movement group (16 cases) and intiative one (16 cases).
Of 29 cases with CTVC proved vesical tumor, the diagnosis was confirmed by FC and/or surgery in 28, and the coincidence rate was 96.5% (28/29). The remaining case was prostatic hyperplasia.
From October 1995 to May 1996, IPSS score, rectal B ultrasonography and urodynamics parameters were used in 46 patients with benign prostatic hypertrophy before prostatectomy, to determine if any could predict voiding function after prostatectomy(IPSS symptom score, prostatic hyperplasia types and follow up results 0.5 ̄7 months).
The efficacy of 1 - Adrenergic receptors(AR) antagonists on the lower urinary tract symptom(LUTS) in patients with benign prostatic hyperplasia(BPH) is widely accepted .
Conclusion:CT is important means for diagnosing the diseases originated from bladder,prostate and seminal vesicle but it does not entirely satisfy early diagnosing prostatomegaly or tumor. Especially,when their border was unclear because of prostate,seminal vesicle and bladder basis conjugating each other into the shadow like a soft tissue mass,it is difficult for CT to differentiate tumor′s outward invasion.
Results Solitary bladder diverticulum were demonstrated in 18 patients,and 6 patients suffered from multiple bladder diverticulum. Among the complications,prostatomegaly was found in 11 cases,prostate hyperplasia in 7 cases,prostatomegaly with calcification in 13 cases,chronic prostatitis in 5 cases,calculus in 2 cases and carcinoma confirmed surgically and pathologically in 2 cases.
GYKI-16084 - (+)-(R)-2-{3-(benzo[1,4]dioxan-2-yl-methylamino)-1-propyl}-3(2H)-pyridazinone hydrochloride - is a new drug candidate for the treatment of benign prostatic hyperplasia.
Urinary incontinence can result following surgical treatment of benign prostatic hyperplasia or prostate cancer and has a significant impact on quality of life.
Failures were due to the inability to gain access to the ureteric orifice because of prostatomegaly (prostate, >amp;gt;100 g) in two cases and a ureteric stricture in two others.